You are here: Industry Insights > Relief Therapeutics

News List

NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19 prnewswire
February 10, 2021
NeuroRx, Inc. reported preliminary results from their Phase 2b/3 trial of ZYESAMI™ (aviptadil, previously RLF-100) performed in collaboration with Relief Therapeutics Holdings, AG (SIX:RLF;OTCQB:RLFTF) in patients with respiratory failure due to ...
NeuroRx, Relief, and Quantum Leap Announce Inclusion of ZYESAMI in I-SPY COVID-19 Trial americanpharmaceuticalreview
January 15, 2021
NeuroRx, Relief Therapeutics, and the Quantum Leap Healthcare Collaborative of San Francisco announce that NeuroRx and QLHC have signed a Clinical Trial Participation Agreement for the inclusion of ZYESAMI™ (RLF-100TM: aviptadil) in the I-SPY COVID-19 ...
NeuroRx and Relief Therapeutics announce enrollment of 150 patients in phase 2b/3 trial of RLF-100™ for Critical COVID-19 with Respiratory Failure prnewswire
November 16, 2020
NeuroRx, Inc. and Relief Therapeutics Holdings AG announced that as of today, 150 patients (out of a targeted enrollment of 165) have been enrolled in the ongoing phase 2b/3 trial of RLF-100™ (aviptadil) for treating respiratory failure in patients with..
FDA Grants Inhaled Use IND for RLF-100 for COVID-19 to Prevent Respiratory Failure americanpharmaceuticalreview
August 12, 2020
NeuroRx and Relief Therapeutics announced NeuroRx has been granted Investigational New Drug (IND) permission to test RLF-100 (aviptadil) for inhaled use in patients with moderate and severe COVID-19 in order to prevent progression to respiratory failure.
RLF-100 shown to deliver rapid recovery from respiratory failure in Covid-19 patients pharmaceutical-business-review
August 07, 2020
NeuroRx and Relief Therapeutics said that RLF-100 (aviptadil) delivered quick recovery from respiratory failure in the most critically ill patients suffering from Covid-19 in a phase 2/3 clinical trial.
NeuroRx, Relief Announce Fast Track Designation for Respiratory Distress Treatment in COVID-19 americanpharmaceuticalreview
July 03, 2020
NeuroRx, in partnership with Relief Therapeutics, announced the U.S. Food and Drug Administration (FDA) awarded Fast Track Designation to NeuroRx for the investigation of RLF-100 (Aviptadil) for the treatment of acute lung injury ...
Relief Therapeutics, NeuroRx Expand Clinical Trial of RLF-100 americanpharmaceuticalreview
June 16, 2020
Relief Therapeutics and its U.S. partner, NeuroRx, announced the Phase 2/3 clinical trial evaluating RLF-100 as a treatment for critical COVID-19 with respiratory failure has been expanded to include patients receiving high flow oxygen and ...
Relief Therapeutics, NeuroRx Begin RLF-100 Study for COVID-19 Associated ARDS americanpharmaceuticalreview
June 10, 2020
Relief Therapeutics and its U.S. partner, NeuroRx, announced treatment of the first patients with RLF-100 at the University of Miami Miller School of Medicine, FL.
Relief Therapeutics, NeuroRx File IND for Aviptadil for COVID-19-Induced Respiratory Distress americanpharmaceuticalreview
April 01, 2020
Relief Therapeutics and NeuroRx have filed an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA) ...
Sonnet BioTherapeutics agrees to buy Relief Therapeutics pharmaceutical-technology
August 14, 2019
Biotechnology company Sonnet BioTherapeutics has agreed to acquire all outstanding shares of Relief Therapeutics under a binding share exchange agreement with Relief Therapeutics Holding.